Pestrec mariánsky – Silybum marianum

Literatúra

  1. Abenavoli L, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. (2010)
  2. Abenavoli L, et al. Complementary therapies for treating alcoholism First Annual meeting by Complementary Medicine Research Group of the Italian Society for Alcohol Studies-May 5, 2006, Florence, Italy. Fitoterapia. (2008)
  3. Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. (2006)
  4. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. (2007)
  5. Kim NC, et al. Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem. (2003)
  6. Lee DY, Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J Nat Prod. (2003)
  7. Membranes and the setting of energy demand.
  8. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev. (2009)
  9. Sheu SY, Lai CH, Chiang HC. Inhibition of xanthine oxidase by purpurogallin and silymarin group. Anticancer Res. (1998)
  10. Pauff JM, Hille R. Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. (2009)
  11. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. (2003)
  12. Tyagi AK, et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. (2002)
  13. Maitrejean M, et al. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett. (2000)
  14. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev. (2004)
  15. Di Pierro F, et al. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes. (2012)
  16. Gurley BJ, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. (2006)
  17. Ka SO, et al. Silibinin attenuates adipogenesis in 3T3-L1 preadipocytes through a potential upregulation of the insig pathway. Int J Mol Med. (2009)
  18. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. (2006)
  19. Zhan T, et al. Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J Cell Biochem. (2011)
  20. Nomura M, et al. Inhibitory mechanisms of flavonoids on insulin-stimulated glucose uptake in MC3T3-G2/PA6 adipose cells. Biol Pharm Bull. (2008)
  21. Sonnenbichler J, Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res. (1986)
  22. Song Z, et al. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol. (2007)
  23. Salamone F, et al. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res. (2012)
  24. Saller R, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. (2008)
  25. Jayaraj R, et al. Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. Environ Toxicol. (2007)
  26. Fausto N, Campbell JS. Mouse models of hepatocellular carcinoma. Semin Liver Dis. (2010)
  27. Brandon-Warner E, et al. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett. (2012)
  28. Bowe WP, Patel N, Logan AC. Acne vulgaris: the role of oxidative stress and the potential therapeutic value of local and systemic antioxidants. J Drugs Dermatol. (2012)
  29. Sahib A, et al. Effects of Oral Antioxidants on Lesion Counts Associated with Oxidative Stress and Inflammation in Patients with Papulopustular Acne. J Clin Exp Dermatol Res. (2012)
  30. Forinash AB, et al. The use of galactogogues in the breastfeeding mother. Ann Pharmacother. (2012)
  31. Low Dog T. The use of botanicals during pregnancy and lactation. Altern Ther Health Med. (2009)
  32. Zapantis A, Steinberg JG, Schilit L. Use of herbals as galactagogues. J Pharm Pract. (2012)
  33. Di Pierro F, et al. Clinical efficacy, safety and tolerability of BIO-C (micronized Silymarin) as a galactagogue. Acta Biomed. (2008)